リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells

Ueda, Tatsuki Shiina, Sara Iriguchi, Shoichi Terakura, Seitaro Kawai, Yohei Kabai, Ryotaro Sakamoto, Satoko Watanabe, Akira Ohara, Kohei Wang, Bo Xu, Huaigeng Minagawa, Atsutaka Hotta, Akitsu Woltjen, Knut Uemura, Yasushi Kodama, Yuzo Seno, Hiroshi Nakatsura, Tetsuya Tamada, Koji Kaneko, Shin 京都大学 DOI:10.1038/s41551-022-00969-0

2023.01

概要

The effectiveness of chimaeric antigen receptor (CAR) T-cell immunotherapies against solid tumours relies on the accumulation, proliferation and persistency of T cells at the tumour site. Here we show that the proliferation of CD8αβ cytotoxic CAR T cells in solid tumours can be enhanced by deriving and expanding them from a single human induced-pluripotent-stem-cell clone bearing a CAR selected for efficient differentiation. We also show that the proliferation and persistency of the effector cells in the tumours can be further enhanced by genetically knocking out diacylglycerol kinase, which inhibits antigen-receptor signalling, and by transducing the cells with genes encoding for membrane-bound interleukin-15 (IL-15) and its receptor subunit IL-15Rα. In multiple tumour-bearing animal models, the engineered hiPSC-derived CAR T cells led to therapeutic outcomes similar to those of primary CD8 T cells bearing the same CAR. The optimization of effector CAR T cells derived from pluripotent stem cells may aid the development of long-lasting antigen-specific T-cell immunotherapies for the treatment of solid tumours.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290–1297 (2011).

2. Gattinoni, L. et al. Wnt signaling arrests efector T cell diferentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808–813 (2009).

3. Klebanof, C. A. et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343–5352 (2011).

4. Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750–3759 (2014).

5. Themeli, M. et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928–933 (2013).

6. Minagawa, A. et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell https://doi.org/10.1016/j. stem.2018.10.005 (2018).

7. Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and rediferentiation. Cell Stem Cell 12, 114–126 (2013).

8. Vizcardo, R. et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. Cell Stem Cell 12, 31–36 (2013).

9. Maeda, T. et al. Regeneration of CD8αβ T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. Cancer Res. 76, 6839–6850 (2016).

10. Kawai, Y. et al. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy. Mol. Ther. 29, 3027–3041 (2021).

11. Iriguchi, S. et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for of-the-shelf T-cell immunotherapy. Nat. Commun. 12, 1–15 (2021).

12. Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).

13. Albert, S. et al. Tonic signaling and its efects on lymphopoiesis of CAR-armed hematopoietic stem and progenitor cells. J. Immunol. 202, 1735–1746 (2019).

14. Maluski, M. et al. Chimeric antigen receptor–induced BCL11B suppression propagates NK-like cell development. J. Clin. Invest. 129, 5108–5122 (2019).

15. Ueda, T. et al. Non–clinical eficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti– glypican-3 chimeric antigen receptor-expressing natural killer/ innate lymphoid cells. Cancer Sci. 111, 1478–1490 (2020).

16. Ueda, N. et al. Generation of TCR-expressing innate lymphoid-like helper cells that induce cytotoxic T cell-mediated anti-leukemic cell response. Stem Cell Rep. 10, 1935–1946 (2018).

17. Kitayama, S. et al. Cellular adjuvant properties, direct cytotoxicity of re-diferentiated Vα24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Rep. 6, 213–227 (2016).

18. Themeli, M., Riviere, I. & Sadelain, M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 16, 357–366 (2015).

19. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).

20. Merida, I., Andrada, E., Gharbi, S. I. & Avila-Flores, A. Redundant and specialized roles for diacylglycerol kinases and in the control of T cell functions. Sci. Signal. 8, re6–re6 (2015).

21. Zha, Y. et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat. Immunol. 7, 1166–1173 (2006).

22. Riese, M. J. et al. Enhanced efector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res. 73, 3566–3577 (2013).

23. Jung, I. Y. et al. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 78, 4692–4703 (2018).

24. Guo, R. et al. Synergistic control of T cell development and tumor suppression by diacylglycerol kinase α and ζ. Proc. Natl Acad. Sci. USA 105, 11909–11914 (2008).

25. Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788–E7797 (2016).

26. Drent, E. et al. Combined CD28 and 4-1BB costimulation potentiates afinity-tuned chimeric antigen receptor-engineered T cells. Clin. Cancer Res. 25, 4014–4025 (2019).

27. Ali, A. K., Nandagopal, N. & Lee, S. H. IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells. Front. Immunol. 6, 1–22 (2015).

28. Fehniger, T. A. et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193, 219–231 (2001).

29. Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/ Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).

30. Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 164, 780–791 (2016).

31. Kaneko, S. Successful organoid-mediated generation of iPSC-derived CAR-T cells. Cell Stem Cell 29, 493–495 (2022).

32. Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697–5705 (2012).

33. Philip, L. P. B. et al. Multiplex genome-edited T-cell manufacturing platform for “of-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 75, 3853–3864 (2015).

34. Ren, J., Zhang, X., Liu, X., Fang, C. & Jiang, S. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget https://doi.org/10.18632/oncotarget.15218 (2017).

35. Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255–2266 (2017).

36. Cherrier, D. E., Serafini, N. & Di Santo, J. P. Innate lymphoid cell development: a T cell perspective. Immunity 48, 1091–1103 (2018).

37. Guo, R. et al. Synergistic control of T cell development and tumor suppression by diacylglycerol kinase and. Proc. Natl Acad. Sci. USA 105, 11909–11914 (2008).

38. Mishra, A. et al. Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma. Cancer Discov. 6, 986–1005 (2016).

39. Paszkiewicz, P. J. et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J. Clin. Invest. 126, 4262–4272 (2016).

40. Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. https://doi.org/10.1038/s41591-019-0421-7 (2019).

41. Ando, M. et al. A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy. Stem Cell Rep. 5, 597–608 (2015).

42. Kaneko, S. et al. IL-7 and IL-15 allow the generation of suicide gene modified alloreactive self-renewing central memory human T lymphocytes. Blood 113, 1006–1015 (2009).

43. Xu, H. et al. Targeted disruption of HLA genes via CRISPR–Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566–578.e7 (2019).

44. Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492–500 (2016).

45. Montel-Hagen, A. et al. Organoid-induced diferentiation of conventional T cells from human pluripotent stem cells. Cell Stem Cell 24, 376–389.e8 (2019).

46. Kowolik, C. M. et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor eficacy of adoptively transferred T cells. Cancer Res. 66, 10995–11004 (2006).

47. Oceguera-Yanez, F. et al. Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their diferentiated derivatives. Methods 101, 43–55 (2016).

48. Kagita, A. et al. Eficient ssODN-mediated targeting by avoiding cellular inhibitory RNAs through precomplexed CRISPR–Cas9/ sgRNA ribonucleoprotein. Stem Cell Rep. 16, 985–996 (2021).

49. Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).

50. Serganova, I. et al. Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1/PD-L1 blockade. Mol. Ther. Oncolytics 4, 41–54 (2016).

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る